Shanghai Fosun Pharmaceutical (Group) Co Class H ( (SFOSF) ) has released its Q4 earnings. Here is a breakdown of the information Shanghai Fosun Pharmaceutical (Group) Co Class H presented to its investors.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading Chinese healthcare company engaged in pharmaceutical manufacturing, medical devices, healthcare services, and pharmaceutical distribution. The company is known for its focus on innovation and strategic transformation in the healthcare sector.
Shanghai Fosun Pharmaceutical has reported its financial results for the year ending December 31, 2024, showcasing a stable performance with a revenue of RMB 40,910 million. The company has emphasized its strategic focus on innovative drugs and high-value medical devices, contributing to its growth in the competitive healthcare market.
Key financial highlights include an operating profit of RMB 2,780 million, a significant increase from RMB 1,100 million in the previous year, and a net profit attributable to shareholders of RMB 2,770 million, marking a 15.46% year-on-year increase. The company’s EBITDA also rose to RMB 8,772 million from RMB 7,720 million. Fosun Pharma has continued to optimize its asset structure, resulting in improved cash flow and operational efficiency.
The company has made significant strides in innovation, with several new drug approvals and launches, including the expansion of indications for its innovative anti-PD-1 monoclonal antibody drug and other biosimilars. This focus on innovation is supported by a robust R&D expenditure of RMB 5,554 million, ensuring the sustainability of its growth strategy.
Looking ahead, Shanghai Fosun Pharmaceutical aims to continue its strategic focus on innovation and efficiency, leveraging its strong R&D capabilities and market presence to drive future growth. The management remains optimistic about the company’s ability to navigate the evolving healthcare landscape and deliver value to its shareholders.